Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature.
Delea
T E
TE
Policy Analysis Inc. (PAI), Brookline, MA, USA. Electronic address: tdelea@pai2.com.
Karnon
J
J
University of Sheffield, School of Health and Related Research, Sheffield, UK.
Goss
P E
PE
Massachusetts General Hospital, Division of Hematology-Oncology, Boston, MA, USA.
D047072:Aromatase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D017698:Postmenopause
D047072:Aromatase Inhibitors